TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.0300nMAssay Description:Tested for binding affinity against HIV proteaseMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.0300nMAssay Description:Tested for binding affinity against HIV proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.0300nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.0300nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.0700nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.200nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.200nMAssay Description:Tested for binding affinity against HIV proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.210nM ΔG°: -57.5kJ/molepH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.210nMAssay Description:Tested for binding affinity against HIV proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.310nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.390nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.390nMAssay Description:Tested for binding affinity against HIV proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.410nM ΔG°: -55.7kJ/mole IC50: 2.20nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.410nMAssay Description:Tested for binding affinity against HIV proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.530nM ΔG°: -55.1kJ/mole IC50: 1.80nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.530nMAssay Description:Tested for binding affinity against HIV proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.670nM ΔG°: -54.5kJ/mole IC50: 2.70nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.670nMAssay Description:Tested for binding affinity against HIV proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.700nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.700nMAssay Description:Tested for binding affinity against HIV proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.830nM ΔG°: -53.9kJ/molepH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 0.830nMAssay Description:Tested for binding affinity against HIV proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 1.04nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 1.10nMAssay Description:Tested for binding affinity against HIV proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 1.10nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 1.40nM ΔG°: -52.6kJ/molepH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 1.40nMAssay Description:Tested for binding affinity against HIV proteaseMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 6.40nMAssay Description:Tested for binding affinity against HIV proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 6.40nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 9.54nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 13nMAssay Description:Tested for binding affinity against HIV proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 13nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 27nM ΔG°: -44.9kJ/molepH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataKi: 27nMAssay Description:Tested for binding affinity against proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 1.30nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 1.30nMAssay Description:Activity of potent nonpeptidic inhibitor against proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 1.5nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 1.5nMAssay Description:Activity of potent nonpeptidic inhibitor against proteaseMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 1.70nMAssay Description:Activity of potent nonpeptidic inhibitor against proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 1.70nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 1.80nMAssay Description:Activity of potent nonpeptidic inhibitor against proteaseMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 1.90nMAssay Description:Activity of potent nonpeptidic inhibitor against proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 1.90nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 1.90nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 1.90nMAssay Description:Activity of potent nonpeptidic inhibitor against proteaseMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 2nMAssay Description:Activity of potent nonpeptidic inhibitor against proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 2nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 2.10nMAssay Description:Activity of potent nonpeptidic inhibitor against proteaseMore data for this Ligand-Target Pair
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 2.10nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 2.20nMAssay Description:Activity of potent nonpeptidic inhibitor against proteaseMore data for this Ligand-Target Pair